

AMENDMENT TRANSMITTAL LETTER

ATTORNEY DOCKET NO.

NOV 25 1998

16715/CIP

Serial No.
08/902,692Filing Date
7/30/97

Examiner

Schwadron, R.

Group Art Unit
1644

INVENTION

AUTOGENOUS LYMPHATIC FACTOR FOR MODIFICATION OF T AND B LYMPHOCYTE PARAMETERS

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

Transmitted herewith is an amendment in the above-identified application.

- Small entity status of this application under 37 CFR 1.27 has been established by a verified statement previously submitted.
- A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
- No additional fee is required.
- The fee has been calculated as shown below:

| | (1) CLAIMS REMAINING AFTER AMENDMENT | (2) HIGHEST NO PREVIOUSLY PAID FOR | (3) PRESENT EXTRA |
|--|--|---|-------------------------|
| TOTAL | 48 | 48 | 0 |
| INDEP | 4 | 4 | 0 |
| FIRST PRESENTATION OF MULTIPLE DEP CLAIM | | | |

| SMALL ENTITY | |
|------------------|----------------|
| RATE | ADDITIONAL FEE |
| x \$11 = | 0 |
| x \$41 = | 0 |
| \$135 | 0 |
| TOTAL ADDIT. FEE | 0 |

| OTHER THAN A SMALL ENTITY | |
|------------------------------|------------|
| OR | RATE |
| | x \$22 = 0 |
| | x \$82 = 0 |
| | \$270 0 |
| OR | TOTAL 0 |

If the entry in Col 1 is less than the entry in Col 2 write "0" in Col 3
 If the Highest No Previously Paid For IN THIS SPACE is less than 20 enter "20"
 If the Highest No Previously Paid For IN THIS SPACE IS LESS THAN 3 ENTER "3"
 The Highest No Previously Paid For (Total or Indep) is the highest number found in Col 1

- Please charge my Deposit Account No. 03-3840 in the amount of \$_____ A duplicate copy of this sheet is enclosed.
- A check in the amount of \$_____ to cover the filing fee is enclosed.
- The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-3840. A duplicate copy of this sheet is enclosed.
- Any additional filing fees required under 37 CFR 1.16.
- Any patent application processing fees under 37 CFR 1.17

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Respectfully submitted,

"EXPRESS MAIL" MAILING LABEL NO. E1807488148US

DATE OF DEPOSIT: November 25, 1998

I HEREBY CERTIFY THAT THE ENCLOSED PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE COMMISSIONER OF PATENTS AND TRADEMARKS, WASHINGTON, D.C.

Virginia Born
Printed Name of Person Mailing Paper or Fee

Virginia Born
Signature of Person Mailing Paper or Fee

Todd E. Albanesi
Todd E. Albanesi, Reg. 36,426
CRUTSINGER & BOOTH
1601 Elm Street, Suite 1950
Dallas, Texas 75201-4744
(214) 220-0444; Fax (214) 220-0445

Attorneys for Applicant

#10a
Graham
12/03/98

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of: William J. Rea, MD, et al
 Serial No.: 08/902,692
 Filed: July 30, 1997

Attorney Docket: 16715/CIP
 Art Group Unit: 1644
 Examiner: Schwadron, R.

**AUTOGENOUS LYMPHATIC FACTOR FOR
 MODIFICATION OF T AND B LYMPHOCYTE PARAMETERS**

**PRELIMINARY AMENDMENT AND
 RESPONSE TO RESTRICTION REQUIREMENT**

Honorable Commissioner of Patents
 and Trademarks
 Washington, D.C. 20231

98 DEC - 2 AM 10:58
 GROUP 180
 RECEIVED

Sir:

In response to the Office Action mailed September 28, 1998, a petition for extension of time being submitted herewith, please amend the above-referenced application as follows:

In the Claims:

a¹
 Claim 22. (AMENDED) A method for regulating an abnormal lymphocytic cell cycle of continuously dividing T and B lymphocytes of a mammal comprising the steps of: obtaining an initial blood sample from the mammal; determining an initial status of the lymphocytic cell cycle of the mammal; administering a treatment of ALF to the mammal; obtaining a second blood sample from the mammal after administering the ALF; and determining a post-treatment status of the lymphocytic cell cycle, whereby the regulatory effect of the ALF treatment on the lymphocytic cell cycle is determined by comparing the initial status of the lymphocytic cell cycle and the post-treatment status of the lymphocytic cell cycle.

a²
 Claim 28. (AMENDED) A method for regulating the abnormal lymphocytic cell cycle of continuously dividing T and B lymphocytic blood cells of a mammal comprising the steps of: obtaining an initial blood sample from the mammal; determining an initial blood status of the lymphocytic cell cycle of the mammal; preparing a lysate from the normal lymphocytes of the blood sample, administering a treatment of the lysate to the mammal; obtaining a second blood sample from the mammal after administering the lysate; and determining a post-treatment status of the lymphocytic